Amanote Research
Register
Sign In
A Long Term Analysis of the Clinical and Cost Effectiveness of Glatiramer Acetate From the Uk Multiple Sclerosis Risk Sharing Scheme
Value in Health
- United Kingdom
doi 10.1016/j.jval.2015.09.2512
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
November 1, 2015
Authors
M Sumra
E Walters
Publisher
Elsevier BV
Related search
Pnd54 - A Long Term Analysis of the Clinical and Cost Effectiveness of Glatiramer Acetate Using Final 10-Year Results From the Uk Multiple Sclerosis Risk Sharing Scheme
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Assessing the Long-Term Effectiveness of Interferon-Beta and Glatiramer Acetate in Multiple Sclerosis: Final 10-Year Results From the UK Multiple Sclerosis Risk-Sharing Scheme
Journal of Neurology, Neurosurgery and Psychiatry
Psychiatry
Mental Health
Neurology
Surgery
Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Journal of Central Nervous System Disease
Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis
Clinical Medicine Insights: Therapeutics
Medicine
Pharmacology
Pharmaceutical Science
UK Multiple Sclerosis Risk-Sharing Scheme: A New Natural History Dataset and an Improved Markov Model
BMJ Open
Medicine
Promoting Oligodendrogenesis and Myelin Repair Using the Multiple Sclerosis Medication Glatiramer Acetate
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Pnd12 - Natalizumab Versus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Risks vs Benefits of Glatiramer Acetate: A Changing Perspective as New Therapies Emerge for Multiple Sclerosis
Therapeutics and Clinical Risk Management
